Clinical Trial

Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL)

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
This study is intend to improve the objective response rate in treatment of camrelizumab in recurrent primary central nervous system lymphoma patients.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2019-08-25; most recent amendment 2024-10-09.
Status change: Not Yet Recruiting → Recruiting 2019-12-12
Trial Details
NCT Number NCT04070040
Lead Sponsor Beijing Sanbo Brain Hospital
Conditions Primary Central Nervous System Lymphoma
Enrollment 21 participants
Start Date 2020-02-13
Primary Completion 2024-12-31 (estimated)
Study Completion 2024-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-15